PMB is thrilled to announce the approval of our Phase 2 clinical trial aimed at investigating the efficacy of Immune 12 in treating Glioblastoma Multiforme (GBM) in Australia…
Registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number ACTRN12624001484538p, this trial will involve 60 patients and marks a significant step in our global research efforts… Patient recruitment is now underway…
As we collaborate with esteemed Australian clinical researchers, we are dedicated to developing a robust protocol that leverages local expertise to enhance treatment outcomes for GBM….
Our commitment to global health is unwavering, and we will maintain the highest standards of patient safety and regulatory compliance throughout this process…
We are excited about the potential this trial holds for advancing cancer treatment and will provide further updates on protocols, trial sites, and timelines as they become available…For inquiries, please contact our principal investigator, Dr. Janet Schloss, at Southern Cross University (janet_schloss@scu.edu.au)…
Together, we aim to bring new hope to cancer patients around the world!
